Research to target new approach to treating liver disease

A new clinical trial, funded by the Efficacy and Mechanism Evaluation (EME) Programme, an MRC and NIHR partnership, will examine the effect of a new antibody therapy, BTT1023 at targeting vascular adhesion protein-1 (VAP-1) in patients with primary sclerosing cholangitis (PSC). PSC is a disease of the bile ducts that restricts the flow of...
Source: NIHR Evaluation, Trials and Studies News - Category: American Health Source Type: news